Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

421 articles

Keyword: tumor immune microenvironmentClear keyword

Bioengineering & translational medicine2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Combined HER2-targeted mRNA-LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights

Wang S, Jing S, Zou S, Zhang Y, Ge M, Gao K, Et Al.

HER2 overexpression is a pivotal oncogenic alteration in NSCLC and is associated with poor prognosis. Existing HER2-targeted therapeutics, including antibody-drug conjugates, have limited anticancer efficacy and prominent systemic toxicity, whereas radiotherapy-mediated tumor immunosuppression further hinders therapeutic outcomes.

HER2 Lewis lung carcinoma mRNA‐LNP vaccine radiotherapy tumor immune microenvironment

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.